Union Square Ventures raised $900 million in new capital, including $500 million for its latest early-stage fund. The firm is also trimming its general partnership to four investors.
Why it matters
A $900M capital raise alongside a partnership reduction signals a deliberate shift toward higher conviction per partner rather than AUM expansion. Allocating $500M specifically to an early-stage fund confirms continued LP appetite for focused seed and Series A execution.
What to watch
How the smaller general partnership impacts check sizes and follow-on strategy across early-stage investments.
New York City venture capital firm Union Square Ventures is nearly doubling the size of its core fund. The firm has also reduced its general partnership team down to four investors to align with its AI investment strategy.
Why it matters
USV's structural pivot toward a smaller partner count alongside a doubled fund size represents a deliberate shift in how top-tier VC firms intend to deploy AI capital. Leaner decision-making units paired with larger check sizes point to tighter conviction management.
What to watch
How USV balances check deployment pace per partner given the expanded fund size and streamlined team.
Endeavor Catalyst raised $320 million to back startup founders outside of Silicon Valley. Half of the fund's profits will be returned to the nonprofit that identifies the founders.
Why it matters
Endeavor's $320 million vehicle reinforces the expanding pool of capital committed to building tech ecosystems outside traditional hubs. Returning half of fund profits to its parent nonprofit provides a structural self-funding engine for global deal sourcing.
What to watch
Whether the non-profit pipeline model yields venture-scale liquidity events comparable to traditional regional VC firms.
French VC firm AdBio is expanding into Canada with a new office in Montréal. Québec fund Fonds de solidarité FTQ is backing AdBio's 120-million-euro Fund III.
Why it matters
European VC expansion into Canada via local LP backing points to transatlantic cross-border venture alliances in life sciences and biotech. Institutional support from Fonds de solidarité FTQ gives AdBio localized deal flow access across Québec.
Capital came in from Canada into a company based in outside the US, Canada and the UK — cross-border participation that widens the pool of investors watching this Canada market.
What to watch
AdBio's first Canadian venture investments and co-investments alongside local biotech funds.
Investment firm 1789 Capital is in talks to raise $3 billion for its second growth fund. The new vehicle will support larger venture investments in startups.
Why it matters
A $3 billion target for a second growth fund marks a dramatic step-up in vehicle size, signalling aggressive expansion into growth-stage check writing. If closed, it adds substantial late-stage dry powder to a venture market that has seen selective deployment at the growth tier.
What to watch
Whether 1789 Capital secures final commitments from major institutional LPs to reach its $3 billion target.
Bessemer Venture Partners is set to announce $5.75 billion in new funding. The capital will support the firm's broader expansion into growth-stage investments.
Why it matters
Bessemer's $5.75 billion pool signals continued institutional LP capital concentration into established multi-stage franchises. Allocating dedicated resources toward growth-stage investments positions the firm to lead larger late-stage rounds directly against crossover funds.
What to watch
How aggressively Bessemer deploys this capital into growth-stage AI deployments versus traditional software rounds.
SoftBank Group Corp. has drawn more than $20 billion in preliminary demand for a major junk bond transaction. The capital raised will help fund the firm's ongoing investments in OpenAI.
Why it matters
SoftBank is leveraging high-yield debt markets at scale to finance mega-cap venture allocations in OpenAI, marking an aggressive return to debt-fueled venture investing. Substantial credit market demand shows broader institutional willingness to indirectly finance frontier AI models.
What to watch
SoftBank's debt servicing exposure if OpenAI's monetization timelines lengthen or primary valuation markups slow.
Amplify Capital is raising a $60-million third impact fund to back up to 30 early-stage companies. The ten-year-old VC firm will focus its investments on climate, health, and work tech.
Why it matters
Amplify Capital's third fund demonstrates sustained LP interest in specialized impact strategies targeting early-stage seed investments. Allocating $60 million across up to 30 companies signals a consistent check size strategy focused on early climate, health, and work platforms.
What to watch
The initial portfolio construction pace and lead check sizes as the firm deploys capital into pre-seed and seed founders.
Valor Equity Partners is handing out stock in SpaceX to its limited partners instead of cash returns.
Why it matters
Distributing equity in-specie lets limited partners retain exposure to high-growth private assets while avoiding forced secondary discounts. It reflects how fund managers navigate extended liquidity windows for mega-cap private companies.
What to watch
Whether more late-stage venture funds replicate in-kind distributions to satisfy LP liquidity demands during prolonged private market cycles.
Bain Capital Ventures raised $1.6 billion for a new fund. The vehicle will target early and growth stage startups focused on the next phase of artificial intelligence technology.
Why it matters
Bain Capital Ventures securing $1.6 billion for next-phase AI deployment proves LP appetite remains high for multi-stage funds targeting frontier technology. Dedicated capital of this scale will drive up valuations and competition for early and growth-stage AI startups.
What to watch
Monitor Bain Capital Ventures' initial deal pace and check size distribution between early-stage application software and growth infrastructure.